Citations

Showing 10 of 108104 citations.

Celebrating Gold: 50 Years of Advancing Perioperative Neuroscience Through the Society for Neuroscience in Anesthesiology and Critical Care
Abcejo, Arnoley S., Cottrell, James, Paisansathan, Chanannait , Cottrell, James

Mayo Clinic

Journal of Neurosurgical Anesthesiology | April 27, 2022 | Volume: 34 | Issue: 3 | Pages: 255-256

10.1097/ana.0000000000000851 | PMID 35476041 Get It

How Do the Outcomes of Radiation-Associated Pelvic and Sacral Bone Sarcomas Compare to Primary Osteosarcomas following Surgical Resection?
Lazarides, Alexander L. , Gundavda, Manit K. , Novak, Rostislav , Ghert, Michelle , Wilson, David , Rose, Peter S. , Wong, Philip , Houdek, Matthew T. , Tsoi, Kim M., Ghert, Michelle , Wong, Philip , Houdek, Matthew T , Tsoi, Kim M , Burke, Zachary D. C. , Griffin, Anthony M. , Ferguson, Peter C. , Wunder, Jay S.

Mayo Clinic

Cancers | April 27, 2022 | Volume: 14 | Issue: 9 | Pages: 2179

10.3390/cancers14092179 | PMID 35565308 Get It

Radiation-associated sarcoma of the pelvis and/or sacrum (RASB) is a rare but challenging disease process associated with a poor prognosis. We hypothesized that patients with RASB would have worse surgical and oncologic outcomes than patients diagnosed with primary pelvic or sacral bone sarcomas. This was a retrospective, multi-institution, comparative analysis. We reviewed surgically treated patients from multiple tertiary care centers who were diagnosed with a localized RASB. We also identified a comparison group including all patients diagnosed with a primary localized pelvic or sacral osteosarcoma/spindle cell sarcoma of bone (POPS). There were 35 patients with localized RASB and 73 patients with POPS treated with surgical resection. Patients with RASB were older than those with POPS (57 years vs. 38 years, p < 0.001). Patients with RASB were less likely to receive chemotherapy (71% for RASB vs. 90% for POPS, p = 0.01). Seventeen percent of patients with RASB died in the perioperative period (within 90 days of surgery) as compared to 4% with POPS (p = 0.03). Five-year disease-specific survival (DSS) (31% vs. 54% p = 0.02) was worse for patients with RASB vs. POPS. There was no difference in 5-year local recurrence free survival (LRFS) or metastasis free survival (MFS). RASB and POPS present challenging disease processes with poor oncologic outcomes. Rates of perioperative mortality and 5-year DSS are worse for RASB when compared to POPS.
Change of Heart: The Underexplored Role of Plaque Hemorrhage in the Evaluation of Stroke of Undetermined Etiology
Holmes, David R. , Alkhouli, Mohamad , Klaas, James P., Brinjikji, Waleed , Savastano, Luis , Lanzino, Giuseppe , Benson, John C. , Alkhouli, Mohamad , Savastano, Luis E , Benson, John , Lanzino, Giuseppe , Klaas, James P., Brinjikji, Waleed

Mayo Clinic

Journal of the American Heart Association | April 27, 2022 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/jaha.122.025323 | PMID 35475334 Get It

In the evaluation of embolic strokes of undetermined source, great emphasis is often placed on cardiovascular disease, namely on atrial fibrillation. Other pathophysiologic mechanisms, however, may also be involved. Carotid artery intraplaque hemorrhage (IPH)—the presence of blood components within an atheromatous plaque—has become increasingly recognized as a possible etiologic mechanism in some cryptogenic strokes. IPH is a marker of plaque instability and is associated with ipsilateral neurologic ischemic events, even in nonstenotic carotid plaques. As recognition of carotid IPH as an etiology of embolic strokes has grown, so too has the complexity with which such patients are evaluated and treated, particularly because overlaps exist in the risk factors for atrial fibrillation and IPH. In this article, we review what is currently known about carotid IPH and how this clinical entity should be approached in the context of the evaluation of embolic strokes of undetermined source.
Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
Chang, Kevin Y. , Duval, Sue , Badesch, David B., Bull, Todd M., Chakinala, Murali M. , Marco, Teresa De , Frantz, Robert P. , Hemnes, Anna R. , Mathai, Stephen C. , Ryan, John , Thenappan, Thenappan , Allen, Roblee P., Bartolome, Sonja, Cadaret, Linda , Eggert, Michael, Elwing, Jean , Fineman, Jeffrey R. , Foley, Raymond , Ford, H. James , Hirsch, Russel, Grinnan, James, Kennedy, Jamie L.W. , Klinger, James R. , Mazimba, Sula , Ramani, Gautam , Raina, Amresh, Runo, James , Swisher, John W. , Varghese, Nidhy P. , White, R.J., Yung, Delphine , Zamanian, Roham T. , Zwicke, Dianne, De Marco, Teresa , Hemnes, Anna , Ryan, John J , Thenappan, Thenappan , Frantz, Robert P , Mathai, Stephen C , Rosenzweig, Erika B. , Benza, Raymond L. , Hirsch, Russel , Ivy, D. Dunbar , Kawut, Steven M. , Leary, Peter J. , White, R. James , Williamson, Timothy L.

Mayo Clinic

Journal of the American Heart Association | April 27, 2022 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/jaha.121.024969 | PMID 35475351 Get It

Background Current mortality data for pulmonary arterial hypertension (PAH) in the United States are based on registries that enrolled patients prior to 2010. We sought to determine mortality in PAH in the modern era using the PHAR (Pulmonary Hypertension Association Registry). Methods and Results We identified all adult patients with PAH enrolled in the PHAR between September 2015 and September 2020 (N=935). We used Kaplan‐Meier survival analysis and Cox proportional hazards models to assess mortality at 1, 2, and 3 years. Patients were stratified based on disease severity by 3 validated risk scores. In treatment‐naïve patients, we compared survival based on initial treatment strategy. The median age was 56 years (44–68 years), and 76% were women. Of the 935 patients, 483 (52%) were ≤6 months from PAH diagnosis. There were 121 deaths (12.9%) during a median follow‐up time of 489 days (281–812 days). The 1‐, 2‐, and 3‐year mortality was 8% (95% CI, 6%–10%), 16% (95% CI, 13%–19%), and 21% (95% CI, 17%–25%), respectively. When stratified into low‐, intermediate‐, and high‐risk PAH, the mortality at 1, 2, and 3 years was 1%, 4% to 6%, and 7% to 11% for low risk; 7% to 8%, 11% to 16%, and 18% to 20% for intermediate risk; and 12% to 19%, 22% to 38%, and 28% to 55% for high risk, respectively. In treatment‐naïve patients, initial combination therapy was associated with better 1‐year survival (adjusted hazard ratio, 0.43 [95% CI, 0.19–0.95]; P =0.037). Conclusions Mortality in the intermediate‐ and high‐risk patients with PAH remains unacceptably high in the PHAR, suggesting the importance for early diagnosis, aggressive use of available therapies, and the need for better therapeutics.
Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease
Leal‐Pardinas, Fernanda, Truty, Rebecca , McKnight, Dianalee , Johnson, Britt , Morales, Ana , Bristow, Sara L. , Pang, Tiffany Yar, Cohen‐Pfeffer, Jessica, Izzo, Emanuela , Sankar, Raman , Koh, Sookyong , Aradhya, Swaroop , Wirrell, Elaine C , Millichap, John , Aradhya, Swaroop , Wirrell, Elaine , Millichap, J Gordon

Mayo Clinic

Epilepsia | April 27, 2022 | Volume: 63 | Issue: 7 | Pages: No page available

10.1111/epi.17269 | PMID 35474188 Get It

AbstractThis study assessed the effectiveness of genetic testing in shortening the time to diagnosis of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease. Individuals who received epilepsy gene panel testing through Behind the Seizure®, a sponsored genetic testing program (Cohort A), were compared to children outside of the sponsored testing program during the same period (Cohort B). Two cohorts were analyzed: children aged ≥24 to ≤60 months with unprovoked seizure onset at ≥24 months between December 2016 and January 2020 (Cohort 1) and children aged 0 to ≤60 months at time of testing with unprovoked seizure onset at any age between February 2019 and January 2020 (Cohort 2). The diagnostic yield in Cohort 1A (n = 1814) was 8.4% (n = 153). The TPP1 diagnostic yield within Cohort 1A was 2.9‐fold higher compared to Cohort 1B (1.0%, n = 18/1814 vs. .35%, n = 8/2303; p = .0157). The average time from first symptom to CLN2 disease diagnosis was significantly shorter than previously reported (9.8 vs. 22.7 months, p < .001). These findings indicate that facilitated access to early epilepsy gene panel testing helps to increase diagnostic yield for CLN2 disease and shortens the time to diagnosis, enabling earlier intervention.
On the calculation of the relative biological effectiveness of ion radiation therapy using a biological weighting function, the microdosimetric kinetic model (MKM) and subsequent corrections (non-Poisson MKM and modified MKM)
Parisi, Alessio , Furutani, Keith M. , Beltran, Chris , Beltran, Chris J , Parisi, Alessio , Furutani, Keith M

Mayo Clinic

Physics in Medicine & Biology | April 27, 2022 | Volume: 67 | Issue: 9 | Pages: 095014

10.1088/1361-6560/ac5fdf | PMID 35474177 Get It

Abstract Objective . To investigate similarities and differences in the formalism, processing, and the results of relative biological effectiveness (RBE) calculations with a biological weighting function (BWF), the microdosimetric kinetic model (MKM) and subsequent modifications (non-Poisson MKM, modified MKM). This includes: (a) the extension of the V79-RBE 10% BWF to model the RBE for other clonogenic survival levels; (b) a novel implementation of MKMs as weighting functions; (c) a benchmark against Chinese Hamster lung fibroblast (V79) in vitro data; (d) a study on the effect of pre- or post- processing the average biophysical quantities used for the RBE calculations; (e) a possible modification of the modified MKM parameters to improve the model accuracy at high linear energy transfer (LET). Methodology . Lineal energy spectra were simulated for two spherical targets (diameter = 0.464 or 1.0 μ m) using PHITS for 1 H, 4 He, 12 C, 20 Ne, 40 Ar, 56 Fe and 132 Xe ions. The results of the in silico calculations were compared with published in vitro data. Main results . All models appear to underestimate the RBE α of hydrogen ions. All MKMs generally overestimate the RBE 50% , RBE 10% and RBE 1% for ions with an LET greater than ∼200 keV μ m −1 . This overestimation is greater for small surviving fractions and is likely due to the assumption of a radiation-independent quadratic term of clonogenic survival ( ß ). The overall RBE trends seem to be best described by the novel ‘post-processing average’ implementation of the non-Poisson MKM. In case of calculations with the non-Poisson MKM, pre- or post- processing the average biophysical quantities affects the computed RBE values significantly. Significance . This study presents a systematic analysis of the formalism and results of widely used microdosimetric models of clonogenic survival for ions relevant for cancer particle therapy and space radiation protection. Points for improvements were highlighted and will contribute to the development of upgraded biophysical models.
Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial
Ekhlaspour, Laya , Raghinaru, Dan, Forlenza, Gregory P. , Kudva, Yogish C. , Lam, David W. , Levister, Camilla, O’Malley, Grenye , Church, Mei Mei , Lum, John W. , Buckingham, Bruce A. , Brown, Sue A. , Church, Mei Mei , Lum, John , Buckingham, Bruce , Forlenza, Gregory P , Isganaitis, Elvira

Mayo Clinic

Journal of Diabetes Science and Technology | April 27, 2022 | Volume: 17 | Issue: 4 | Pages: 935-942

10.1177/19322968221089361 | PMID 35473359 Get It

Background: We investigated the potential benefits of automated insulin delivery (AID) among individuals with type 1 diabetes (T1D) in sub-populations of baseline device use determined by continuous glucose monitor (CGM) use status and insulin delivery via multiple daily injections (MDI) or insulin pump. Materials and Methods: In a six-month randomized, multicenter trial, 168 individuals were assigned to closed-loop control (CLC, Control-IQ, Tandem Diabetes Care), or sensor-augmented pump (SAP) therapy. The trial included a two- to eight-week run-in phase to train participants on study devices. The participants were stratified into four subgroups: insulin pump and CGM (pump+CGM), pump-only, MDI and CGM (MDI+CGM), and MDI users without CGM (MDI-only) users. We compared glycemic outcomes among four subgroups. Results: At baseline, 61% were pump+CGM users, 18% pump-only users, 10% MDI+CGM users, and 11% MDI-only users. Mean time in range 70-180 mg/dL (TIR) improved from baseline in the four subgroups using CLC: pump+CGM, 62% to 73%; pump-only, 61% to 70%; MDI+CGM, 54% to 68%; and MDI-only, 61% to 69%. The reduction in time below 70 mg/dL from baseline was comparable among the four subgroups. No interaction effect was detected with baseline device use for TIR ( P = .67) or time below ( P = .77). On the System Usability Questionnaire, scores were high at 26 weeks for all subgroups: pump+CGM: 87.2 ± 12.1, pump-only: 89.4 ± 8.2, MDI+CGM 87.2 ± 9.3, MDI: 78.1 ± 15. Conclusions: There was a consistent benefit in patients with T1D when using CLC, regardless of baseline insulin delivery modality or CGM use. These data suggest that this CLC system can be considered across a wide range of patients.
Post-operative Monitoring for Head and Neck Microvascular Reconstruction in the Era of Resident Duty Hour Restrictions: A Retrospective Cohort Study Comparing 2 Monitoring Protocols
Anagnos, Vincent , Carey, Ryan M. , Ravin, Emma De , Tasche, Kendall K. , Newman, Jason G. , Shanti, Rabie M., Chalian, Ara A., Rassekh, Christopher H. , Weinstein, Gregory S., O’Malley, Bert W. , Cannady, Steven B., Anagnos, Vincent J , De Ravin, Emma , Brody, Robert M.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | April 27, 2022 | Volume: 132 | Issue: 3 | Pages: 310-316

10.1177/00034894221088176 | PMID 35473389 Get It

Objectives: To determine whether 2 different methods of post-operative head and neck free flap monitoring affect flap failure and complication rates. Methods: A retrospective chart review of 803 free flaps performed for head and neck reconstruction by the same microvascular surgeon between July 2013 and July 2020 at 2 separate hospitals within the same healthcare system. Four-hundred ten free flaps (51%) were performed at Hospital A, a medical center where flap checks were performed at frequent, scheduled intervals by in-house resident physicians and nurses; 393 free flaps (49%) were performed at Hospital B, a medical center where flap checks were performed regularly by nursing staff with resident physician evaluation as needed. Total free flap failure, partial free flap failure, and complications (consisting of wound infection, fistula, and reoperation within 1 month) were assessed. Results: There were no significant differences between Hospitals A and B when comparing rates of total free flap failure, partial free flap failure, complication, or re-operation ( P = .27, P = .66, P = .65, P = .29, respectively). There were no significant differences in urgent re-operation rates for flap compromise secondary to thrombosis and hematoma ( P = .54). Conclusions: In our series, free flap outcomes did not vary based on the degree of flap monitoring by resident physicians. This data supports the ability of a high-volume, well-trained, nursing-led flap monitoring program to detect flap compromise in an efficient fashion while limiting resident physician obligations in the age of resident duty hour restrictions.
Intraoperative Capnothorax during Robotic Diaphragmatic Endometriosis Excision
Dunn, Tyler , Misra, Lopa

Mayo Clinic

Case Reports in Anesthesiology | April 26, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-3

10.1155/2022/5935312 | PMID 35520147 Get It

Laparoscopic surgery is performed quite commonly and is known to have numerous advantages over traditional open surgery. Albeit rare, there are life-threatening complications as a result of laparoscopic surgery including those associated with the cardiopulmonary system. In our case, we present hemodynamically unstable capnothorax that occurred during robotic diaphragmatic endometriosis excision which was treated conservatively. It is critical for anesthesia providers to recognize when capnothorax occurs and to understand the implications and treatment in order to minimize unnecessary procedures and morbidity associated with such.